769 results on '"Yu, Menggang"'
Search Results
52. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis
53. Developing New Methods for Determining Treatment Benefits Based on Individual Patient Traits
54. Follow-up Care Strategies After Treatment for Breast Cancer
55. Associations between specialty care and improved outcomes among patients with diabetic foot ulcers.
56. Relative contrast estimation and inference for treatment recommendation.
57. Entropy balancing for causal generalization with target sample summary information.
58. Supplementary Table 2 from Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts
59. Data from Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts
60. Supplementary Table 1 from Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts
61. Supplementary Figure 1 from Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts
62. Dual Axl/ MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer
63. The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT‐01)
64. Abstract P5-02-47: Quantitative proteomic analysis of plasma exosomes from patients with advanced hormone receptor-positive/HER2-negative breast cancer receiving palbociclib and tamoxifen
65. Abstract P4-01-38: A single arm phase II trial of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer
66. Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).
67. A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC).
68. Regularized Outcome Weighted Subgroup Identification for Differential Treatment Effects
69. Group Variable Selection Via Convex Log-Exp-Sum Penalty with Application to a Breast Cancer Survivor Study
70. Marginal and Conditional Distribution Estimation from Double-sampled Semi-competing Risks Data
71. Local/Regional Recurrence Rates After Breast-Conserving Therapy in Patients Enrolled in Legacy Trials of the Alliance for Clinical Trials in Oncology (AFT-01)
72. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma
73. Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802)
74. Meta-Analysis Based Variable Selection for Gene Expression Data
75. [Discussion on "Combining Biomarkers to Optimize Patient Treatment Recommendations"]
76. Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.
77. On the effect of electronic patient portal on primary care utilization and appointment adherence
78. Utility of Clinical Breast Examinations in Detecting Local–Regional Breast Events After Breast-Conservation in Women with a Personal History of High-Risk Breast Cancer
79. Smoking Status, Nicotine Medication, Vaccination, and COVID-19 Hospital Outcomes: Findings from the COVID EHR Cohort at the University of Wisconsin (CEC-UW) Study
80. Relations of Current and Past Cancer with Severe Outcomes among 104,590 Hospitalized COVID-19 Patients: The COVID EHR Cohort at the University of Wisconsin
81. Risk factors associated with distress among postoperative patients in an academic gynecologic oncology practice (482)
82. Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer
83. Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non–Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77
84. Adjusted regression estimation for time-to-event data with differential measurement error
85. Smoking Status, Nicotine Medication, Vaccination, and COVID-19 Hospital Outcomes: Findings from the COVID EHR Cohort at the University of Wisconsin (CEC-UW) Study.
86. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
87. Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database
88. Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx
89. Risk of Advanced Neoplasia Using the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool
90. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer.
91. A generalizability score for aggregate causal effect.
92. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
93. Impactability Modeling for Reducing Medicare Accountable Care Organization Payments and Hospital Events in High-Need High-Cost Patients: Longitudinal Cohort Study
94. Results of the safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA 1/2 positive HER2 negative breast cancer.
95. Adjuvant immunotherapy in patients with high‐risk muscle‐invasive urothelial carcinoma: The potential impact of informative censoring
96. Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer
97. Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation
98. Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma
99. Buckley—James Type Estimator for Censored Data with Covariates Missing by Design
100. Additional file 1 of Which test for crossing survival curves? A user���s guideline
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.